文献速递泌尿生殖与妇科肿瘤放疗

质子放疗用于宫颈癌与子宫内膜癌术后盆腔放疗的前瞻性II期APROVE研究

Prospective phase-II-study evaluating postoperative radiotherapy of cervical and endometrial cancer patients using protons - the APROVE-trial.
PubMed 文献 · Radiat Oncol · 2017-11-28

APROVE研究是一项前瞻性单中心单臂II期试验,纳入25例宫颈癌或子宫内膜癌术后需盆腔放疗的患者,以质子治疗替代常规光子放疗,处方剂量45-50.4 GyE,分次1.8 GyE,每周5-6次,采用主动扫描笔形束质子技术。主要终点为安全性及治疗耐受性,即无CTC AE 3级或4级毒性;次要终点包括临床症状与毒性、生活质量及无进展生存。

要点

  • 质子盆腔放疗处方剂量45-50.4 GyE,1.8 GyE/次,每周5-6次。
  • 主要终点为无CTC AE 3级或4级毒性的安全性与耐受性。
  • 计划纳入25例宫颈癌或子宫内膜癌术后患者。

核心结论

  • 旨在探索质子治疗作为宫颈癌和子宫内膜癌术后盆腔放疗新方法,降低肠道、直肠和膀胱剂量从而减少急慢性毒性并改善生活质量。

研究设计与样本

  • APROVE为前瞻性单中心单臂II期研究,计划纳入25例术后需盆腔放疗的宫颈癌或子宫内膜癌患者,以质子治疗替代常规光子放疗。
  • 处方剂量45-50.4 GyE,分次1.8 GyE,每周5-6次,采用主动扫描笔形束质子放疗;必要时可行铂类化疗。
  • 危及器官包括直肠、乙状结肠、大小肠、膀胱和股骨头,CTV按RTOG共识指南定义。

主要发现

  • 文献报道需医疗处理的并发症发生率为0.7-8%,5年后7.7%的患者出现严重并发症,且每年并发症风险增加0.3%。
  • 小肠和大肠接受低剂量(15 Gy)照射的体积已被证明是发生更高肠道毒性的预测因素。

关键数值与推荐

  • 主要终点为盆腔质子放疗的安全性和治疗耐受性,定义为无任何CTC AE 3级或4级毒性。
  • 次要终点为临床症状与毒性、生活质量及无进展生存。

临床怎么用

  • 对于宫颈癌或子宫内膜癌术后有盆腔放疗指征的患者,可考虑采用质子治疗以更好地保护肠道、直肠和膀胱等危及器官。
  • 治疗计划中应将直肠、乙状结肠、大小肠、膀胱和股骨头定义为危及器官,CTV按RTOG共识指南勾画。
  • 根据临床指征可联合铂类化疗。

局限性

  • 本研究为单中心、单臂II期试验,计划样本量仅25例。
  • 主要终点为安全性与耐受性,非疗效终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognosis for patients with cervical or endometrial cancer has improved over the last decades. Thus, reducing therapy-related toxicity and impact on quality of life have become more and more important. With the development of new radiotherapy techniques like IMRT (Intensity-modulated radiotherapy) the incidence of acute and chronic toxicities has already been reduced. Nevertheless, rates of complications requiring medical treatment range from 0.7-8% according to literature. 7.7% of patients develop severe complications after 5 years with an increasing risk for complications of 0.3%/year. Particularly, the volume of the small and large bowel receiving low doses (15 Gy) has been shown to be a predictive factor for the development of higher bowel toxicity. With the introduction of proton therapy into clinical practice, there are new opportunities for optimization of organ at risk-sparing thus possibly reducing toxicity. METHODS/DESIGN: The APROVE study is a prospective single-center one-arm phase-II-study. Patients with cervical or endometrial cancer after surgical resection who have an indication for postoperative pelvic radiotherapy will be treated with proton therapy instead of the commonly used photon radiation. A total of 25 patients will be included in this trial. Patients will receive a dose of 45-50.4 GyE in 1.8 GyE fractions 5-6 times per week using active raster-scanning pencil beam proton radiation. Platinum-based chemotherapy can be administered if indicated. For treatment planning, rectum, sigma, large and small bowel, bladder and femoral heads are defined as organs at risk. The CTV is defined according to the RTOG consensus guidelines. DISCUSSION: The primary endpoint of the study is the evaluation of safety and treatment tolerability of pelvic radiation using protons defined as the lack of any CTC AE Grade 3 or 4 toxicity. Secondary endpoints are clinical symptoms and toxicity, quality of life and progression-free survival. The aim is to explore the potential of proton therapy as a new method for adjuvant pelvic radiotherapy to decrease the dose to the bowel, rectum and bladder thus reducing acute and chronic toxicity and improving quality of life. TRIAL REGISTRATION: Registered at https://clinicaltrials.gov , ClinicalTrials.gov Identifier: NCT03184350 , registered 09 June 2017, enrolment of the first participant 19 June 2017.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Arians N, Lindel K, Krisam J, et al. Prospective phase-II-study evaluating postoperative radiotherapy of cervical and endometrial cancer patients using protons - the APROVE-trial. Radiat Oncol. 2017. PMID: 29179751. doi:10.1186/s13014-017-0926-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。